Valneva SE (VLA)
Vienna Exchange · Austria · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 2.422 |
|---|---|
| 52-week range | 2.048 – 5.115 |
| Return, 1 month / 3 months | −14.7% / +12.3% |
| Return, 1 year / 3 years | −42.0% / −51.6% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 81.3% |
| Worst drawdown (1 year) | -58.6% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Valneva SE is a vaccine company based in France that develops and makes vaccines for infectious diseases. Its products include vaccines against cholera and Japanese encephalitis, and it has developed a vaccine for chikungunya. The company serves public health authorities, governments and healthcare providers in markets around the world, and it also works on travel-related and specialty vaccines for people at risk of exposure to infectious diseases.
On this site Valneva SE appears as a stock on the Vienna Exchange (Austria), code VLA, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Valneva SE (VLA) trades on the Vienna Exchange in Austria. It last closed at EUR 2.422 on 22 October 2026.
Its price-based Market X-Ray is 27 out of 100 (a weak price profile), ranking 75 of 84 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 42.0% and over the last three months it rose 12.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Vienna Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 13 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.1% | ||
| From 52-week high | -52.5% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 12.3% | ||
| 6-month return | 2.0% | ||
| 12-month return, skipping the last month | -32.0% | ||
| Stability (higher is calmer) | 8 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 81.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -58.6% | ||
| Liquidity | 43 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −8.6% |
|---|---|
| 1 month | −14.7% |
| 3 months | +12.3% |
| 6 months | +2.0% |
| 1 year | −42.0% |
| 3 years | −51.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 2.772 / 2.994 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.113 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Vienna Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.